Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
CNI-1493-CD05 is an open-label extension study of CNI-1493-CD04. In the CD05 study, patients
are eligible for up to 5 courses of semapimod 60 mg IV x 3 days every 6 - 8 weeks. Primary
objective is assessment of the efficacy of cumulative doses of semapimod measured by decrease
in Crohn's Disease Activity Index (CDAI).